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Purpose of the study
Tuberculosis (TB) is common in HIV-infected patients
and associated with advanced immunosuppression. The
optimal HIV treatment in patients receiving TB therapy
remains to be defined.
Methods
We reviewed all HIV/TB patients who received NNRTI-
based antiretroviral therapy (ART) together with TB ther-
apy at two London HIV clinics from 2000 to 2007. Base-
line characteristics, TB outcome, trends in CD4 T-cell
count and HIV-RNA level, and liver enzymes were exam-
ined.
Summary of results
Analysis is still in progress and for this abstract restricted
to one clinical site where 70 patients were identified.
Mean age was 36 yrs, 54% were female, 79% black Afri-
can, 5% IVDU, 5% were hepatitis B and 6% hepatitis C co-
infected. Efavirenz (n = 46) or nevirapine (n = 24) was
given at a dose of 800 mg and 600 mg daily respectively
to patients taking rifampicin (91%). Of the 70 patients,
51 initiated ART after having started TB therapy (median
time to HIV therapy 8 weeks). NNRTI were well tolerated;
two patients switched from efavirenz to nevirapine, one
discontinued HAART due to life-threatening IRIS, five
switched to a PI, and two died. Median CD4 count at TB
diagnosis and 3, 6, 9 and 12 months post-ART initiation
were 61, 158, 208, 256 and 296 cells/mm3, respectively,
and 91% of patients attained an HIV-RNA <50 c/mL. CD4
and HIV-RNA responses did not differ between patients
who received efavirenz or nevirapine. Grade 3 or 4 AST
was observed in five patients each and was associated with
hepatitis co-infection but not nevirapine use. A further 19
patients developed TB while receiving NNRTI-based ART
(after a median duration of 15.1 (IQR 5–29) months.
Median CD4 count in these patients was 279 cells/mm3,
and 67% had HIV-RNA levels <50 c/mL. TB occurred <3
months of ART initiation in six patients, two of whom
died. All others attained or maintained undetectable HIV-
RNA levels, and no significant toxicity was observed.
Conclusion
In conclusion, NNRTI-based ART is highly effective in
patients co-infected with TB/HIV. Co-administration of
rifampicin and nevirapine was not associated with an
increased incidence of liver toxicity.
from Ninth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 9–13 November 2008
Published: 10 November 2008
Journal of the International AIDS Society 2008, 11(Suppl 1):P260 doi:10.1186/1758-2652-11-S1-P260
<supplement> <title> <p>Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection</p> </title> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1758-2652-11-S1-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1758-2652-11-S1-info.pdf</url> </supplement>
This abstract is available from: http://www.jiasociety.org/content/11/S1/P260
© 2008 Campbell et al; licensee BioMed Central Ltd. 
